Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Conditions: Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Nab paclitaxel; Drug: Docetaxel; Drug: Gemcitabine; Drug: Etoposide; Drug: Irinotecan; Drug: Topotecan; Drug: Lurbinectedin Sponsor: Fox Chase Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Conditions: Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation Interventions: Biological: Toripalimab; Drug: Nab paclitaxel; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Guangdong Provincial People's Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer Interventions: Drug: fianlimab; Drug: cemiplimab; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Drug: Cisplatin; Drug: Placebo Sponsor: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Conditions: Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation Interventions: Biological: Toripalimab; Drug: Nab paclitaxel; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Guangdong Provincial People's Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Conditions: Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Nab paclitaxel; Drug: Docetaxel; Drug: Gemcitabine; Drug: Etoposide; Drug: Irinotecan; Drug: Topotecan; Drug: Lurbinectedin Sponsor: Fox Chase Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Conditions: Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation Interventions: Biological: Toripalimab; Drug: Nab paclitaxel; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Guangdong Provincial People's Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer Interventions: Drug: fianlimab; Drug: cemiplimab; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Drug: Cisplatin; Drug: Placebo Sponsor: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Conditions: Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation Interventions: Biological: Toripalimab; Drug: Nab paclitaxel; Drug: Pemetrexed; Drug: Carboplatin Sponsors: Guangdong Provincial People's Hospital; Shanghai Junshi Bioscience Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Conditions: Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Nab paclitaxel; Drug: Docetaxel; Drug: Gemcitabine; Drug: Etoposide; Drug: Irinotecan; Drug: Topotecan; Drug: Lurbinectedin Sponsor: Fox Chase Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2023 Category: Research Source Type: clinical trials
An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
Condition: Advanced Solid Tumor Interventions: Biological: Adebrelimab; Biological: SHR-1802; Drug: Carboplatin/Cisplatin; Drug: Paclitaxel/Nab-Paclitaxel/Pemetrexed Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2023 Category: Research Source Type: clinical trials
